(Total Views: 473)
Posted On: 08/03/2019 1:17:53 PM
Post# of 72446
This is why they are planning an oral ulcerative colitis trial:
Deal terms should be much better than UP.
Looks like their trial sequence jumped from 1B to 2B/3 for ulcerative colitis.
https://www.fiercebiotech.com/biotech/janssen...h-up-to-1b
https://investor.theravance.com/news-releases...-four-week
https://clinicaltrials.gov/ct2/show/NCT028186...amp;rank=4
Deal terms should be much better than UP.
Looks like their trial sequence jumped from 1B to 2B/3 for ulcerative colitis.
https://www.fiercebiotech.com/biotech/janssen...h-up-to-1b
https://investor.theravance.com/news-releases...-four-week
https://clinicaltrials.gov/ct2/show/NCT028186...amp;rank=4
(1)
(0)
